Understanding where resM fits requires being honest about what it can and cannot replace
Several major randomized controlled trials (RCTs) have confirmed the efficacy and safety of GLP-1RAs in adults with diabetes 17 and obesity 18 , and more recently in child and adolescent populations living with obesity 19,20
The recommended infusion rate given under Dosage and Administration in the prescribing information must be closely followed
According to the data provided by the Synapse Database, As of June 13, 2024, there are 52 investigational drugs for the GIPR and GLP-1R target, including 33 indications, 42 R&D institutions involved, with related clinical trials reaching 196, and as many as 1806 patents
Menopause: identification and management (NG23) Recommendations